Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

Figure 6

Cross-sectional analysis of T-cell counts and counts of seven subpopulations of CD4+ T-cells stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3+ T-cells at visits 8 and 10, (b) CD3 + CD4+ T-helper cells at visits 8 and 10, (c) CD4 + CD45RA + CD45RO-naïve T-helper cells at visit 8, (d) CD4+ CD45RA+ CD45RO+ double positive intermediate T-helper cells at visit 8, (e) CD4 + CD45RA + CD62L+ naïve T-helper cells at visit 8, (f) CD4 + CD45RA + CD62L-terminally differentiated effector memory T-helper cells at visit 8, (g) CD4 + CD62L-effector memory T-helper cells at visit 8, and (h) CD4 + CD62L+ naïve T-helper cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and values for these results are provided in the figure, and complete results are presented in the Supplementary Table 2.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)